Bookmark and Share

ALEMTUZUMAB Drug Information Page

Updated 11/08/2010 12:12:41 AM

ProductSourceDateLinkData
ALEMTUZUMABMHRA2009-3-4ALEMTUZUMAB-MHRA-2009-3-4MHRA has issued drug updates: Methylphenidate: updated guidance on safe and effective use in ADHD Atomoxetine: risk of psychotic or manic symptoms Antipsychotics: use in elderly patients with dementia Exenatide (Byetta): risk of severe pancreatitis and renal failure Bisphosphonates: atypical stress fractures Efalizumab (Raptiva): recommendation to suspend marketing authorisation Patient-controlled analgesia extension sets: risk of inadequate pain relief Effects of MRI on implantable drug pumps Oral bowel cleansing solutions: risk of harm
ALEMTUZUMABHealth Canada2008-11-21ALEMTUZUMAB-Health Canada-2008-11-21Bayer HealthCare and Genzyme, in collaboration with Health Canada, has informed Canadian healthcare professionals of important safety information concerning the use of MABCAMPATH� (alemtuzumab) following treatment with other anti-leukemia drugs which also suppress the body's immune system. MABCAMPATH is currently used to treat patients with B-cell chronic lymphocytic leukemia (B-CLL), a blood cancer affecting a certain type of white blood cells called B-lymphocytes, when other drugs to treat this type of cancer have been unsuccessful.

Joining this website will allow you to recieve emails about any pharmaceutial you are interested in or you can search for other pharmaceuticals on this website. Joining should only take 2 minutes.



Image of checkdrugs.com Logo
© Cardan Technologies Inc

This site is presented as an educational source only and you use it at your own risk. The information on this site is not a substitute for a visit with your doctor or pharmacist. Always talk to your doctor before changing medications or dosage, or if you experience any serious side effects.